CD19 and cancer: To date, more than 35 clinical trials using CAR NK cells are conducted (clinicaltrials.gov) against several cancer epitopes, such as CD19, CD19/22, CD33, CD7, HER2, MUC1, PDL1, NKG2D ligand, BCMA, ROBO1, PSMA, mesothelin and others using CAR NK cells from different sources, primary human NK cells, cord-blood derived and iPSC-derived NK cells as well as CARs from the cell line NK92 (141, 142).